Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?

Literature DB >> 11312237

Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?

N Freemantle¹.

Abstract

Mesh：

Year: 2001 PMID： 11312237 PMCID： PMC1120143 DOI： 10.1136/bmj.322.7292.989

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

15 in total

1. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme.

Authors: S R Hill; A S Mitchell; D A Henry
Journal: JAMA Date: 2000-04-26 Impact factor: 56.272

2. The evidence for beta blockers in heart failure.

Authors: J G Cleland; J McGowan; A Clark; N Freemantle
Journal: BMJ Date: 1999-03-27

3. A consumer's guide to subgroup analyses.

Authors: A D Oxman; G H Guyatt
Journal: Ann Intern Med Date: 1992-01-01 Impact factor: 25.391

4. No adjustments are needed for multiple comparisons.

Authors: K J Rothman
Journal: Epidemiology Date: 1990-01 Impact factor: 4.822

5. Estimation issues in clinical trials and overviews.

Authors: S J Pocock; M D Hughes
Journal: Stat Med Date: 1990-06 Impact factor: 2.373

6. Something rotten in the state of clinical and economic evaluations?

Authors: N Freemantle; A Maynard
Journal: Health Econ Date: 1994 Mar-Apr Impact factor: 3.046

7. The FDA's critique of the anturane reinfarction trial.

Authors: R Temple; G W Pledger
Journal: N Engl J Med Date: 1980-12-18 Impact factor: 91.245

8. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors: M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal: N Engl J Med Date: 1996-10-10 Impact factor: 91.245

9. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

Authors: A Hjalmarson; S Goldstein; B Fagerberg; H Wedel; F Waagstein; J Kjekshus; J Wikstrand; D El Allaf; J Vítovec; J Aldershvile; M Halinen; R Dietz; K L Neuhaus; A Jánosi; G Thorgeirsson; P H Dunselman; L Gullestad; J Kuch; J Herlitz; P Rickenbacher; S Ball; S Gottlieb; P Deedwania
Journal: JAMA Date: 2000-03-08 Impact factor: 56.272

10. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640

33 in total

1. Evaluating guidelines across primary care-secondary care interface. Methodological weaknesses and poor reporting undermine authors' conclusions.

Authors: N Freemantle; J Wood
Journal: BMJ Date: 2001-10-06

2. A fair innings for NICE?

Authors: Nick Freemantle; Karen Bloor; Joanne Eastaugh
Journal: Pharmacoeconomics Date: 2002 Impact factor: 4.981

Review 3. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?

Authors: Nick Freemantle
Journal: BMJ Date: 2005-10-08

Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?

1. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme.

2. The evidence for beta blockers in heart failure.

3. A consumer's guide to subgroup analyses.

4. No adjustments are needed for multiple comparisons.

5. Estimation issues in clinical trials and overviews.

6. Something rotten in the state of clinical and economic evaluations?

7. The FDA's critique of the anturane reinfarction trial.

8. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

9. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

10. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

1. Evaluating guidelines across primary care-secondary care interface. Methodological weaknesses and poor reporting undermine authors' conclusions.

2. A fair innings for NICE?

Review 3. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?

4. Real-world trials to answer real-world questions.

5. Is a subgroup claim believable? A user's guide to subgroup analyses in the surgical literature.

6. Vitamin D and tuberculosis.

7. What can we do about exploratory analyses in clinical trials?

Review 8. Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.

Review 9. Guidelines for the Reporting of Treatment Trials for Alcohol Use Disorders.

Review 10. Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.